GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) recently announced the launch of its Herpes Zoster vaccine (Shingles vaccine), Shingrix (MAL24056002ARZ), also known as Recombinant Zoster Vaccine, Adjuvanted (RZV) in Malaysia.
GSK Shingles vaccine
This Shingles vaccine is designed to prevent shingles (herpes zoster, HZ) and post-herpetic neuralgia (PHN) in adults aged 50 years and over. RZV is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses. This is a significant step in public health, especially for older adults who face a higher risk of these painful conditions.
RZV will initially be available in Malaysia to adults aged 50 and over, as well as those aged 18 and over who are at increased risk of HZ. Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox. As people age, the cells in the immune system lose the ability to mount a strong and effective response to infections, increasing the risk of developing shingles. This disease can cause unbearable pain, often described as worse than labor pain, and in some cases, can lead to post-herpetic neuralgia (PHN), a long-lasting nerve pain that follows shingles.
It’s worth noting that RZV has demonstrated impressive vaccine efficacy, up to 97% in adults aged 50 and above over a follow-up period of approximately three years, according to the pivotal efficacy studies ZOE-50. Recent interim data showed that RZV maintains an efficacy of greater than 80% even six to ten years after the initial vaccination. This long-lasting protection is crucial, especially given how debilitating shingles can be.
Dr. Alap Gandhi, Country Medical Director of GSK Malaysia, emphasized, “Shingles is a disease that can cause excruciating pain and is caused by the reactivation of the varicella-zoster virus. RZV has been designed to boost the immune response to the virus in people aged 50 and over or in those with immunocompromised conditions.” His statement reflects the importance of RZV as a preventive measure that can significantly reduce the burden of this painful disease.
Personally, it’s encouraging to see vaccines like RZV become available, especially for those who might be more vulnerable to severe complications from shingles. This vaccine combines a non-live antigen with GSK’s adjuvant, which may help overcome the natural age-related decline in immunity, addressing a major challenge in protecting older adults. It’s not just about reducing pain; it’s about improving quality of life, especially in our aging population.
RZV has received positive vaccination recommendations and is now endorsed by the Guideline for Adult Immunization by the Malaysia Society of Infectious Diseases and Chemotherapy for individuals 50 years and above, as well as immunosuppressed patients aged 18 and above. With the launch of RZV in Malaysia, GSK continues to play a significant role in enhancing public health, providing critical preventive options against a disease that can severely impact one’s daily life.
GSK Shingles Vaccine, Shingrix, is now available in hospitals and clinics near you.
0 Comments